PAVBLU Q Code: Q5147

Drug & Product Overview

HCPCS Descriptor Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg

HCPCS Added Date April 1, 2025

Manufacturer Amgen

Route of Administration Intravitreal

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About PAVBLU

Pavblu is a medication aligned to the HCPCS Q Code: Q5147 for billing, pricing, and reimbursement purposes in the United States. This Ophthalmology medication is administered via the intravitreal route and manufactured by Amgen.

According to CMS Drug Use Information: Aflibercept is used to treat certain serious eye conditions (such as macular edema/degeneration, diabetic retinopathy, retinopathy of prematurity). This medication can help preserve vision and prevent blindness. Aflibercept belongs to a class of drugs known as growth factor inhibitors. It works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels. This monograph is about the following aflibercept products: aflibercept, aflibercept-ayyh.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
55513-0056-01	Pavblu	Amgen, Inc	2	2 MG / 0.05 ML
55513-0065-01	Pavblu	Amgen, Inc	2	2 MG / 0.05 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

PAVBLU Pricing & Reimbursement

Q5147 Private Payer Reimbursement

$866.15 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Aflibercept Biosimilar Information:

PAVBLU Approval Date: August 23, 2024

Product Name	HCPCS Code	Active Ingredient	BLA Type
Eylea	J0178	Aflibercept	351(a) Originator Product
Opuviz	Q5153	Aflibercept	351(k) Interchangeable
Yesafili	Q5155	Aflibercept	351(k) Interchangeable
Ahzantive	Q5150	Aflibercept	351(k) Biosimilar
Enzeevu	Q5149	Aflibercept	351(k) Biosimilar
Pavblu	Q5147	Aflibercept	351(k) Biosimilar
Eydenzelt	Q5170	Aflibercept	351(k) Biosimilar

PAVBLU CPT Administration Codes

CPT Code	Description
67028	Intravitreal injection of a pharmacologic agent (separate procedure) 67028

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

PAVBLU Medically Unlikely Edits (MUE)

The most billing units of Q5147 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

4 units / day

= 4 mg per day

MAI 2 · Date of Service Edit: Policy. Absolute per-day limit set by policy or regulation; units above it are not payable, and denials are not appealable on medical-necessity grounds. See all MUE limits →

PAVBLU Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Macular Edema Following Retinal Vein Occlusion (RVO) Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Drug Class

Vascular Endothelial Growth Factor Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitors [MoA]

Frequently Asked Questions

Is there a manufacturer-published PAVBLU billing and coding guide?

Billing and coding information for PAVBLU can be found through Amgen Inc. Visit Here →

What are the available PAVBLU patient assistance programs?

PAVBLU patient assistance information can be found through Amgen Inc. Visit Here →

Where can I find PAVBLU prescribing information?

PAVBLU prescribing information can be found at the link below. Visit Here →

Where can I find PAVBLU side effect information?

Our team has not identified a source of side effect information for PAVBLU.

Does billing PAVBLU require JZ/JW wastage modifiers?

CMS does not include PAVBLU (Q5147) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5147. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.